The Future of Drug Discovery

Who Decides Which Diseases to Treat?

Tamas Bartfai, Graham V. Lees

• Publisher: Academic Press
• Year: 2013
• Print ISBN:
  9780124071803
• eBook ISBN:
  9780124095199
• Topic: Medicine
• Subtopic: Pharmacology

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. - Provides an in-depth, broad perspective on the crisis in drug industry - Exposes the disconnect between what society needs and what the drug companies are working on - Analyses and projects over 10 years into the future - Explains what it means for scientists and society - Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat

Index

Note: Page numbers followed by “f” and “t” indicate figures and tables respectively.

A

Academia–industry collaborations

drug candidate, 207

government funding, 203

industry researchers, 204–205

open-ended collaborations, 206

patent applications, 206–207

pharma companies, 204

R&D project processes, 204

in vitro testing, 208

Acetylcholine esterase inhibitors (AChEIs), 157

AChEIs, See Acetylcholine esterase inhibitors

Actelion, 283

AD, See Alzheimer’s disease

ADC, See Antibody-drug conjugate

ADHD, See Attention deficit hyperactivity disorder

Adverse drug reactions

goods and services, 241

pharmacogenomics, 240–241

Age as risk factor

advanced drug treatments, 27

drug-producing part, 27–28

early treatments, 27

neurodegenerative diseases, 27

patient–doctor interactions, 27

risks facing, 27–28

Age-related macular degeneration (AMD), 69

Aging population, 32

AD, 32

drug needs, 32–33

Airliners, 197

ALCL, See Anaplastic large cell lymphoma

Alzheimer’s Association, 228

Alzheimer’s Association International Conference on Alzheimer’s Disease 2010 (AAICAD 2010), 228

Alzheimer’s disease (AD), 32, 148

Big Pharma, role in, 297

diagnostics in oncology, 154

effects on world, 148

full-genome sequences, 153

genetic forms, 155

genetic predisposition, 155

genetic risk factor, 228

memantine, 152

mutations, 153–154

neurodegenerative disease, 151

patients care, 151–152

predictive genes, 228

sporadic forms, 152

therapy, 157–158

anti-amyloid treatment, 280–281

tarenflurbil (Flurizan), avoid, 178–179

treatment and prevention of, 228

Alzheimer’s Disease Foundation, 195–197

Alzheimer’s Prevention Initiative (API), 280–281

AMD, See Age-related macular degeneration

Amyloid, 155–156, 180

Amyloid beta peptide (Aβ peptide), 155, 179

AD, in slow disease progression, 209–210

Amyloid peptide, inhibition, 155–156

Amyloid plaques, 155–156

Amyloid precursor protein

mutations in, 153–154

plaques, 155

Amyloidogenic Abeta 1-40/42 peptides, 155, 179...

Table of contents

• Cover image
• Title page
• Table of Contents
• Expert Reviews for The Future of Drug Discovery: Who Decides Which Diseases to Treat?
• Dedication
• Copyright
• Preface
• Foreword by Graeme Bilbe PhD
• Foreword by James H Eberwine PhD
• Foreword by Eduard Enrico Holdener MD
• Chapter 00: Introduction
• Chapter 01. Why there will be new drugs despite the ongoing “crisis” of drug development in Big Pharma
• Chapter 02. The need for medicines grows
• Chapter 03. Medicines are becoming better: some of the breakthrough medicines of the past decades
• Chapter 04. Which diseases do we want to treat?
• Chapter 05. Therapeutic areas: Strategically important diseases of the future
• Chapter 06. Blockbuster proprietary drugs versus generic drugs
• Chapter 07. Why is pharma a special industry?
• Chapter 08. Diagnosing toward personalized medicine
• Chapter 09. Personalized medicine
• Chapter 10. How much can drugs cost?
• Chapter 11. Modeling drug discovery until 2025
• Chapter 12. Drug development models between 2010 & 2025
• Index